These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23226058)

  • 1. Role of cytochrome P450 genotype in the steps toward personalized drug therapy.
    Cavallari LH; Jeong H; Bress A
    Pharmgenomics Pers Med; 2011; 4():123-36. PubMed ID: 23226058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population.
    Arici M; Özhan G
    Saudi Pharm J; 2017 Mar; 25(3):376-380. PubMed ID: 28344492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
    Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
    J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
    Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
    Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical application of pharmacogenomics.
    Ma JD; Lee KC; Kuo GM
    J Pharm Pract; 2012 Aug; 25(4):417-27. PubMed ID: 22689709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
    Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
    Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
    Skadrić I; Stojković O
    Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
    Seeringer A; Kirchheiner J
    Internist (Berl); 2008 Jul; 49(7):877-83. PubMed ID: 18551264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
    López-García MA; Feria-Romero IA; Serrano H; Rayo-Mares D; Fagiolino P; Vázquez M; Escamilla-Núñez C; Grijalva I; Escalante-Santiago D; Orozco-Suarez S
    Pharmacol Rep; 2017 Jun; 69(3):504-511. PubMed ID: 28343093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.